Management of Clostridioides difficile Infection: Diagnosis, Treatment, and Future Perspectives.

Moises Auron, Michael Cymbal, Brian Baggott, Arjun Chatterjee

Journal: The American journal of medicine 2024;137(7):571-576

PMID: 38508330

Abstract

Clostridioides difficile infection is the most common healthcare-associated infection in the United States, with potential life-threatening complications and a significant impact on the costs of care. Antibiotic stewardship as well as discontinuation of chronic acid suppressive therapy are key for its prevention and treatment. Effective infection management requires appropriate interpretation of diagnostic tests, as well as the use of vancomycin and fidaxomicin as first-line treatment. Novel treatments such as Bezlotoxumab, fecal microbiota transplant, and live biotherapeutic products are proven effective in recurrent C. difficile infection and address dysbiosis.

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Address: Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.; Department of Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, Ohio.; Department of Hospital Medicine, Cleveland Clinic, Cleveland, Ohio; Outcomes Research Consortium, Cleveland, Ohio. Electronic address: [email protected].

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.